Product Name: MARK1 (24-43)
Product Number: PE-01BDQ90
| Size: | 1 mg | Price: | 112.00 | |
| 5 mg | $US | 264.00 | ||
| 20 mg | 416.00 |
Peptide Name: MARK1 (24-43)
Product Use: Services as a blocking peptide for use with the MARK1-ANT rabbit polyclonal antibody (Cat. No.: AB-NK098-2) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: YTEPHIQPTKSSSRQNIPRC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2341.6 Da
Peptide Purity Percent after Synthesis and Purification: >90
Product Use: Services as a blocking peptide for use with the MARK1-ANT rabbit polyclonal antibody (Cat. No.: AB-NK098-2) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: YTEPHIQPTKSSSRQNIPRC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2341.6 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: MARK1 pan-specific antibody (Cat. No.: AB-NK098-2)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: MARK1 pan-specific antibody (Cat. No.: AB-NK098-2)
Scientific Background: MARK1 is a protein-serine/threonine kinase that is is a member of the CAMK group of protein kinases in the CAMKL family, and MARK subfamily. It mediates control of cell polarity and microtubule function. This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. It is activated by phosphorylation on T215 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. MARK1 phosphorylates microtubule-associated proteins and trigger microtubule disruption. Gene mutation studies performed in mice revealed that after targeted disruption of the MARK1 gene, the mice lacked the ability to drink, and displayed hind leg motor dysfunction. Genetic variations in MARK1 have been correlated with susceptibility to autism. MARK1 is over-expressed in the prefrontal cortex of autism patients and affects the function of cortical dendrites. MARK1 has also been linked with the development of gastric adenocarcinomas and ovarian serous carcinomas.
© Kinexus Bioinformatics Corporation 2017